Comparison of the effect of oral sotalol and oral metoprolol succinate in the prevention of atrial fibrillation after coronary artery bypass surgery.

Evaluation of the effect of oral sotalol in comparison with oral metoprolol succinate in prevention of atrial fibrillation in patients after coronary artery bypass graft surgery

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231123060154N1

Enrollment

188

Registered

2023-12-03

Start date

2023-12-22

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: coronary artery bypass graft. Condition 2: Atrial fibrillation and flutter. Atherosclerosis of coronary artery bypass graft(s) and coronary artery of transplanted heart with angina pectoris Atrial fibrillation and flutter

Interventions

Intervention 1: Intervention group: Sotalol tablets are prescribed 24 hours before surgery and up to 3 days after surgery. Sotalol is started with a dose of 40 mg per day and is increased or decreased

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who are candidates for CABG

Exclusion criteria

Exclusion criteria: Previous history of atrial fibrillation Having a permanent pacemaker Any definite or probable evidence of having any type of ventricular or supraventricular arrhythmia Moderate and severe LV enlargement Moderate and severe valvular heart disease acute MI Prolonged QT Patients with severe renal impairment and ESRD Asthma and bronchospasm Patients with hemodynamic disorders and low blood pressure Patients who are taking drugs that interact with sotalol will be excluded from the study if it is not possible to stop the drug. These drugs include: All QT prolonging drugs including: Amiodarone, Amisulpride, Azithromycin, Carbetocin, Ceritinib, Chloroquine, Citalopram, Clarithromycin, Clofazimine, Clomipramine, Clozapine, Dabrafenib, Dasatinib, Domperidone, Doxepine-containing products, Droperidol, Encorafenib, Entrectinib ) Nilotinib, Olanzapine, Ondansetron, Osimertinib, Oxytocin, Pacritinib, Pazopanib, Pentamidine, Pilsicainide, Pimozide, Piperaquine, Probucul, Propafenone, Propofol, Quetiapine, Ribociclib, risperidone, Sertindole, Sparfloxacin, Sunitinib, Terbutaline, Thioridazine, Toremifene, Vemurafenib : Alfuzocin, Alpha1- Blockers, Amifostine, Phenothiazines, Barbiturates, Benperidol, Levodpa- Containing products, Lormetazepam, Methoxyflurane, Molsidomine, Naftopidil, Nicergoline, Nicorandil, Nifedipine, Nitroprusside, Obinutuzumab, Pentoxyfilline, Pholcodine, Phosphodiesterase 5 inhibitors, Prostacyclin, Quinagolide, Reserpine: Acetylcholinesterase inhibitors, Ceritinib, Dipyridamole, Etilefrine, Ivabradine, Lacosamide, Midodrine, Ozanimod, Ponesimod, Siponimod, Blood sugar lowering drugs: Insulins, Sulfonylureas, Antidiabetic agents

Design outcomes

Primary

Measure	Time frame
Occurrence of atrial fibrillation. Timepoint: Patients are continuously cardiac monitored for atrial fibrillation. Method of measurement: ECG.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contacthadi naderi

Qazvin University of Medical Sciences

naderihd@gmail.com+98 28 3332 6034

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026